Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)

Adjunctive Treatment of Major Depressive Disorder Clinical Trial

Official title:
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder

Status Completed

Clinical Trial Summary

To assess the efficacy of pimavanserin compared to placebo when given adjunctively to a selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant as treatment of patients with Major Depressive Disorder (MDD) and an inadequate response to antidepressant therapy

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Adjunctive Treatment of Major Depressive Disorder
Depression
Depressive Disorder
Depressive Disorder, Major
Disease

Clinical Trial Details

NCT number	NCT03018340
Study type	Interventional
Source	ACADIA Pharmaceuticals Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	December 2016
Completion date	October 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04103892` - A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study	Phase 2
Terminated	`NCT04000009` - Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment	Phase 3
Completed	`NCT03999918` - Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment	Phase 3
Completed	`NCT03968159` - Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment	Phase 3